Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):489–497. doi: 10.1038/bjc.1995.99

Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.

S Souès 1, F Laval 1, J Y Charcosset 1
PMCID: PMC2033653  PMID: 7880729

Abstract

We have isolated from Chinese hamster ovary cells, 30 sublines resistant to vincristine, doxorubicin or etoposide and 43 sublines evading treatment with a pair of these drugs. Isolated in one step and under low selective pressure, sublines were 3- to 25-fold more resistant to their selecting drug(s) than the parental cells. Possible P-glycoprotein-associated multidrug resistance was investigated through pgp gene copy number and mRNA expression level. DNA topoisomerase II alteration was evaluated from the ability of nuclear extracts to form cleavable complexes. Vincristine (all sublines) and doxorubicin (6/7 sublines) preferentially selected for pgp gene amplification and mRNA overexpression, whereas selection with etoposide resulted in a decrease of cleavable complex formation in 11 out of 13 sublines. A common pgp gene-mediated resistance was found in the 13 doxorubicin plus vincristine-selected sublines, whereas all but one of the 12 etoposide plus vincristine-resistant sublines displayed both pgp mRNA overexpression and decreased ability to form cleavable complexes. Among the 18 doxorubicin plus etoposide selected sublines, five exhibited a decreased ability to form cleavable complexes only, six exhibited pgp mRNA overexpression only and six exhibited both alterations. Overall, drug resistance could not be attributed to either mechanism in three of the 73 sublines. We conclude that under low selective pressure it is possible to find a combination of drugs which require simultaneous selection of more than one resistance mechanism; such cells emerge with very low frequency.

Full text

PDF
489

Images in this article

491Figure 1
on p.491
491Figure 2
on p.491
492Figure 4
on p.492
493Figure 5
on p.493
493Figure 6
on p.493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrand M. A., Heppell-Parton A. C., Wright K. A., Rabbitts P. H., Twentyman P. R. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994 Jan 19;86(2):110–117. doi: 10.1093/jnci/86.2.110. [DOI] [PubMed] [Google Scholar]
  2. Berlin V., Haseltine W. A. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem. 1981 May 25;256(10):4747–4756. [PubMed] [Google Scholar]
  3. Biedler J. L. Drug resistance: genotype versus phenotype--thirty-second G. H. A. Clowes Memorial Award Lecture. Cancer Res. 1994 Feb 1;54(3):666–678. [PubMed] [Google Scholar]
  4. Bradley G., Naik M., Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 1989 May 15;49(10):2790–2796. [PubMed] [Google Scholar]
  5. Bugg B. Y., Danks M. K., Beck W. T., Suttle D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7654–7658. doi: 10.1073/pnas.88.17.7654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Charcosset J. Y., Saucier J. M., Jacquemin-Sablon A. Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. Biochem Pharmacol. 1988 Jun 1;37(11):2145–2149. doi: 10.1016/0006-2952(88)90573-4. [DOI] [PubMed] [Google Scholar]
  7. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  8. Corbett A. H., Hong D., Osheroff N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem. 1993 Jul 5;268(19):14394–14398. [PubMed] [Google Scholar]
  9. Danks M. K., Schmidt C. A., Cirtain M. C., Suttle D. P., Beck W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988 Nov 29;27(24):8861–8869. doi: 10.1021/bi00424a026. [DOI] [PubMed] [Google Scholar]
  10. Danks M. K., Warmoth M. R., Friche E., Granzen B., Bugg B. Y., Harker W. G., Zwelling L. A., Futscher B. W., Suttle D. P., Beck W. T. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 1993 Mar 15;53(6):1373–1379. [PubMed] [Google Scholar]
  11. Dautry F., Weil D., Yu J., Dautry-Varsat A. Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem. 1988 Nov 25;263(33):17615–17620. [PubMed] [Google Scholar]
  12. Devine S. E., Melera P. W. Functional studies with a full-length P-glycoprotein cDNA encoded by the hamster pgp1 gene. Cancer Chemother Pharmacol. 1994;33(6):465–471. doi: 10.1007/BF00686502. [DOI] [PubMed] [Google Scholar]
  13. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  14. Ferguson P. J., Fisher M. H., Stephenson J., Li D. H., Zhou B. S., Cheng Y. C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988 Nov 1;48(21):5956–5964. [PubMed] [Google Scholar]
  15. Fernandes D. J., Danks M. K., Beck W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry. 1990 May 1;29(17):4235–4241. doi: 10.1021/bi00469a028. [DOI] [PubMed] [Google Scholar]
  16. Georges E., Sharom F. J., Ling V. Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol. 1990;21:185–220. doi: 10.1016/s1054-3589(08)60343-9. [DOI] [PubMed] [Google Scholar]
  17. Giaccone G., Gazdar A. F., Beck H., Zunino F., Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 1992 Apr 1;52(7):1666–1674. [PubMed] [Google Scholar]
  18. Giulotto E., Knights C., Stark G. R. Hamster cells with increased rates of DNA amplification, a new phenotype. Cell. 1987 Mar 13;48(5):837–845. doi: 10.1016/0092-8674(87)90080-8. [DOI] [PubMed] [Google Scholar]
  19. Glisson B. S., Killary A. M., Merta P., Ross W. E., Siciliano J., Siciliano M. J. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol. 1992;31(2):131–138. doi: 10.1007/BF00685100. [DOI] [PubMed] [Google Scholar]
  20. Glisson B., Gupta R., Smallwood-Kentro S., Ross W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 1986 Apr;46(4 Pt 2):1934–1938. [PubMed] [Google Scholar]
  21. Goldie J. H., Coldman A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984 Sep;44(9):3643–3653. [PubMed] [Google Scholar]
  22. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  23. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994 Jan 15;54(2):357–361. [PubMed] [Google Scholar]
  24. Haim N., Nemec J., Roman J., Sinha B. K. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res. 1987 Nov 15;47(22):5835–5840. [PubMed] [Google Scholar]
  25. Harker W. G., Slade D. L., Drake F. H., Parr R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry. 1991 Oct 15;30(41):9953–9961. doi: 10.1021/bi00105a020. [DOI] [PubMed] [Google Scholar]
  26. Hill B. T., Deuchars K., Hosking L. K., Ling V., Whelan R. D. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst. 1990 Apr 4;82(7):607–612. doi: 10.1093/jnci/82.7.607. [DOI] [PubMed] [Google Scholar]
  27. Hinds M., Deisseroth K., Mayes J., Altschuler E., Jansen R., Ledley F. D., Zwelling L. A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991 Sep 1;51(17):4729–4731. [PubMed] [Google Scholar]
  28. Hooper M. L., Subak-Sharpe J. H. Metabolic cooperation between cells. Int Rev Cytol. 1981;69:45–104. doi: 10.1016/s0074-7696(08)62320-7. [DOI] [PubMed] [Google Scholar]
  29. Hosking L. K., Whelan R. D., Shellard S. A., Davies S. L., Hickson I. D., Danks M. K., Hill B. T. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Int J Cancer. 1994 Apr 15;57(2):259–267. doi: 10.1002/ijc.2910570222. [DOI] [PubMed] [Google Scholar]
  30. Houghton J. A., Houghton P. J., Hazelton B. J., Douglass E. C. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins. Cancer Res. 1985 Jun;45(6):2706–2712. [PubMed] [Google Scholar]
  31. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. 1985 Aug 29-Sep 4Nature. 316(6031):820–823. doi: 10.1038/316820a0. [DOI] [PubMed] [Google Scholar]
  32. Lemontt J. F., Azzaria M., Gros P. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res. 1988 Nov 15;48(22):6348–6353. [PubMed] [Google Scholar]
  33. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  34. Long B. H., Wang L., Lorico A., Wang R. C., Brattain M. G., Casazza A. M. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991 Oct 1;51(19):5275–5283. [PubMed] [Google Scholar]
  35. Matsuo K., Kohno K., Takano H., Sato S., Kiue A., Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res. 1990 Sep 15;50(18):5819–5824. [PubMed] [Google Scholar]
  36. McPherson J. P., Brown G. A., Goldenberg G. J. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus. Cancer Res. 1993 Dec 15;53(24):5885–5889. [PubMed] [Google Scholar]
  37. Muller C., Laval F., Soues S., Birck C., Charcosset J. Y. High cell density-dependent resistance and P-glycoprotein-mediated multidrug resistance in mitoxantrone-selected Chinese hamster cells. Biochem Pharmacol. 1992 May 28;43(10):2091–2102. doi: 10.1016/0006-2952(92)90166-g. [DOI] [PubMed] [Google Scholar]
  38. Ng W. F., Sarangi F., Zastawny R. L., Veinot-Drebot L., Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol. 1989 Mar;9(3):1224–1232. doi: 10.1128/mcb.9.3.1224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ohnuma T., Arkin H., Holland J. F. Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect). Br J Cancer. 1986 Sep;54(3):415–421. doi: 10.1038/bjc.1986.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pain J., Sirotnak F. M., Barrueco J. R., Yang C. H., Biedler J. L. Altered molecular properties of tubulin in a multidrug-resistant variant of Chinese hamster cells selected for resistance to vinca alkaloids. J Cell Physiol. 1988 Aug;136(2):341–347. doi: 10.1002/jcp.1041360218. [DOI] [PubMed] [Google Scholar]
  41. Patel S., Fisher L. M. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer. 1993 Mar;67(3):456–463. doi: 10.1038/bjc.1993.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Politi P. M., Arnold S. T., Felsted R. L., Sinha B. K. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol Pharmacol. 1990 Jun;37(6):790–796. [PubMed] [Google Scholar]
  43. Rappa G., Lorico A., Sartorelli A. C. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Cancer Res. 1992 May 15;52(10):2782–2790. [PubMed] [Google Scholar]
  44. Rice G. C., Ling V., Schimke R. T. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9261–9264. doi: 10.1073/pnas.84.24.9261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. 1985 Aug 29-Sep 4Nature. 316(6031):817–819. doi: 10.1038/316817a0. [DOI] [PubMed] [Google Scholar]
  46. Ritke M. K., Roberts D., Allan W. P., Raymond J., Bergoltz V. V., Yalowich J. C. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer. 1994 Apr;69(4):687–697. doi: 10.1038/bjc.1994.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Schneider E., Horton J. K., Yang C. H., Nakagawa M., Cowan K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994 Jan 1;54(1):152–158. [PubMed] [Google Scholar]
  48. Schneider E., Hsiang Y. H., Liu L. F. DNA topoisomerases as anticancer drug targets. Adv Pharmacol. 1990;21:149–183. doi: 10.1016/s1054-3589(08)60342-7. [DOI] [PubMed] [Google Scholar]
  49. Singh B., Gupta R. S. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res. 1983 Feb;43(2):577–584. [PubMed] [Google Scholar]
  50. Sinha B. K., Chignell C. F. Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. Chem Biol Interact. 1979 Dec;28(2-3):301–308. doi: 10.1016/0009-2797(79)90170-4. [DOI] [PubMed] [Google Scholar]
  51. Sinha B. K., Haim N., Dusre L., Kerrigan D., Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 1988 Sep 15;48(18):5096–5100. [PubMed] [Google Scholar]
  52. Sinha B. K., Myers C. E. Irreversible binding of etoposide (VP-16-213) to deoxyribonucleic acid and proteins. Biochem Pharmacol. 1984 Nov 15;33(22):3725–3728. doi: 10.1016/0006-2952(84)90166-7. [DOI] [PubMed] [Google Scholar]
  53. Sirotnak F. M., Yang C. H., Mines L. S., Oribé E., Biedler J. L. Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamster cells selected for resistance to vinca alkaloids. J Cell Physiol. 1986 Feb;126(2):266–274. doi: 10.1002/jcp.1041260217. [DOI] [PubMed] [Google Scholar]
  54. Slapak C. A., Daniel J. C., Levy S. B. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res. 1990 Dec 15;50(24):7895–7901. [PubMed] [Google Scholar]
  55. Souès S., Charcosset J. Y. Simultaneous resistance to vincristine and adriamycin appears at higher frequencies than to vincristine and etoposide in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1993 Aug 31;195(1):65–71. doi: 10.1006/bbrc.1993.2010. [DOI] [PubMed] [Google Scholar]
  56. Sullivan D. M., Eskildsen L. A., Groom K. R., Webb C. D., Latham M. D., Martin A. W., Wellhausen S. R., Kroeger P. E., Rowe T. C. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol. 1993 Feb;43(2):207–216. [PubMed] [Google Scholar]
  57. Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991 Aug 1;51(15):3951–3957. [PubMed] [Google Scholar]
  58. Thompson L. H., Baker R. M. Isolation of mutants of cultured mammalian cells. Methods Cell Biol. 1973;6:209–281. doi: 10.1016/s0091-679x(08)60052-7. [DOI] [PubMed] [Google Scholar]
  59. Thompson L. H., Fong S., Brookman K. Validation of conditions for efficient detection of HPRT and APRT mutations in suspension-cultured Chinese hamster ovary cells. Mutat Res. 1980 Feb;74(1):21–36. doi: 10.1016/0165-1161(80)90188-0. [DOI] [PubMed] [Google Scholar]
  60. Webb C. D., Latham M. D., Lock R. B., Sullivan D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 1991 Dec 15;51(24):6543–6549. [PubMed] [Google Scholar]
  61. Zaman G. J., Versantvoort C. H., Smit J. J., Eijdems E. W., de Haas M., Smith A. J., Broxterman H. J., Mulder N. H., de Vries E. G., Baas F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993 Apr 15;53(8):1747–1750. [PubMed] [Google Scholar]
  62. de Jong S., Zijlstra J. G., de Vries E. G., Mulder N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990 Jan 15;50(2):304–309. [PubMed] [Google Scholar]
  63. van der Zee A. G., de Jong S., Keith W. N., Hollema H., Boonstra H., de Vries E. G. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 1994 Feb 1;54(3):749–755. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES